PTCT

64.49

1.78% 1.13

Dopo l'orario di chiusura: 64.49

Ptc Therapeutics Inc (PTCT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché PTCT Giù? Forum Previsione

Precedente Chiudi:

$63.36

Aprire:

$63.91

Volume 24 ore:

605.69K

Relative Volume:

0.50

Capitalizzazione di mercato:

$5.34B

Reddito:

$1.73B

Utile/perdita netta:

$682.64M

Rapporto P/E:

8.3359

EPS:

7.7364

Flusso di cassa netto:

$411.18M

1 W Prestazione:

+2.66%

1M Prestazione:

-7.14%

6M Prestazione:

+5.57%

1 anno Prestazione:

+22.23%

Intervallo 1D:

$63.80

$65.78

Intervallo di 1 settimana:

$62.13

$71.00

Portata 52W:

$35.95

$87.50

Ptc Therapeutics Inc Stock (PTCT) Company Profile

Nome

Ptc Therapeutics Inc

Settore

Healthcare (1116)

Industria

Biotechnology (621)

Telefono

(908) 222-7000

Indirizzo

500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ

Dipendente

991

Cinguettio

@PTCBio

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

PTCT's Discussions on Twitter

Compare PTCT vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PTCT Ptc Therapeutics Inc	64.49	5.34B	1.73B	682.64M	411.18M	7.7364
VRTX Vertex Pharmaceuticals Inc	469.34	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.51B	5.36B	287.73M	924.18M	2.5229

Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-28	Ripresa	Barclays	Overweight
2025-12-01	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-10-20	Iniziato	Wells Fargo	Overweight
2025-06-17	Iniziato	Truist	Buy
2025-05-09	Aggiornamento	BofA Securities	Neutral → Buy
2025-05-07	Aggiornamento	Citigroup	Sell → Neutral
2025-03-11	Aggiornamento	BofA Securities	Underperform → Neutral
2025-03-07	Iniziato	Scotiabank	Sector Perform
2024-12-13	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2024-12-03	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2024-10-10	Ripresa	Raymond James	Mkt Perform
2024-09-04	Iniziato	Robert W. Baird	Outperform
2024-08-26	Ripresa	UBS	Buy
2024-05-20	Aggiornamento	Raymond James	Underperform → Mkt Perform
2023-12-19	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2023-12-08	Iniziato	Wells Fargo	Overweight
2023-10-30	Aggiornamento	Oppenheimer	Perform → Outperform
2023-10-27	Downgrade	Citigroup	Neutral → Sell
2023-10-06	Downgrade	Truist	Buy → Hold
2023-09-18	Downgrade	Citigroup	Buy → Neutral
2023-09-15	Downgrade	Raymond James	Outperform → Underperform
2023-03-17	Iniziato	SVB Securities	Market Perform
2022-12-14	Iniziato	Goldman	Sell
2022-09-12	Iniziato	Jefferies	Buy
2022-09-09	Iniziato	Morgan Stanley	Equal-Weight
2022-09-01	Iniziato	Citigroup	Buy
2022-04-04	Ripresa	Cantor Fitzgerald	Overweight
2021-10-18	Downgrade	BofA Securities	Neutral → Underperform
2021-04-26	Ripresa	Credit Suisse	Neutral
2021-03-29	Aggiornamento	RBC Capital Mkts	Underperform → Sector Perform
2021-02-12	Downgrade	BofA Securities	Buy → Neutral
2021-01-05	Aggiornamento	Citigroup	Neutral → Buy
2020-11-30	Downgrade	RBC Capital Mkts	Sector Perform → Underperform
2020-10-30	Downgrade	Citigroup	Buy → Neutral
2020-10-28	Iniziato	UBS	Neutral
2020-10-07	Aggiornamento	JP Morgan	Neutral → Overweight
2020-08-25	Iniziato	Raymond James	Outperform
2020-04-09	Aggiornamento	Citigroup	Neutral → Buy
2020-02-20	Downgrade	Citigroup	Buy → Neutral
2020-02-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2019-11-12	Iniziato	SunTrust	Buy
2019-05-13	Aggiornamento	BofA/Merrill	Neutral → Buy
2019-04-11	Iniziato	Bernstein	Outperform
2018-10-03	Aggiornamento	BofA/Merrill	Underperform → Neutral
2018-10-01	Iniziato	Cantor Fitzgerald	Overweight
2018-07-19	Iniziato	Credit Suisse	Outperform
2018-06-18	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2018-04-04	Downgrade	Barclays	Equal Weight → Underweight
2018-01-29	Ripresa	RBC Capital Mkts	Sector Perform
2017-11-16	Aggiornamento	JP Morgan	Underweight → Neutral
2017-10-26	Downgrade	BofA/Merrill	Neutral → Underperform
2017-10-09	Downgrade	JP Morgan	Neutral → Underweight

Mostra tutto

Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie

09:22 AM

What PTC Therapeutics (PTCT)'s FDA Leadership Shift Means For Its Gene and RNA Pipeline Narrative - simplywall.st

09:22 AM

Mar 13, 2026

Matthew Klein Sells 2,662 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat

Mar 13, 2026

PTC Therapeutics (PTCT) CEO logs RSU vesting and automatic tax share sale - Stock Titan

Mar 13, 2026

Stephanie Okey Sells 15,167 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat

Mar 12, 2026

B. Metzler seel. Sohn & Co. AG Invests $944,000 in PTC Therapeutics, Inc. $PTCT - MarketBeat

Mar 12, 2026

Mar 11, 2026

FDA ‘blacklist’ in DMD? Legislator slams PTC turndown - bioworld.com

Mar 11, 2026

PTC Therapeutics at Barclays Conference: Sephience’s Global Potential By Investing.com - Investing.com Canada

Mar 11, 2026

PTCT: Sepiapterin’s rapid PKU launch drives strong growth, with global expansion and pipeline progress - TradingView

Mar 11, 2026

PTCT Earnings History & Surprises | EPS & Revenue Results | PTC THERAPEUTICS INC (NASDAQ:PTCT) - ChartMill

Mar 11, 2026

PTC Therapeutics Stock Soars 8.88%, Hits Intraday High of $69.17 - Markets Mojo

Mar 11, 2026

Mar 10, 2026

PTC Therapeutics at Leerink Conference: Strategic Growth in PKU Market By Investing.com - Investing.com Canada

Mar 10, 2026

PTC Therapeutics (+8.9%): FDA Leadership Change Spurs Sector-Wide Rally - Trefis

Mar 10, 2026

Mar 09, 2026

(PTCT) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Mar 09, 2026

Lee Scott Golden Sells 10,000 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat

Mar 09, 2026

Neil Gregory Almstead Sells 3,989 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat

Mar 09, 2026

Executive stock sale by PTC Therapeutics (PTCT) Chief Medical Officer - Stock Titan

Mar 09, 2026

PTC Therapeutics (PTCT) CTO spouse sells shares under 10b5-1 trading plan - Stock Titan

Mar 09, 2026

PTC Therapeutics (NASDAQ:PTCT) Shares Up 6.9%Time to Buy? - MarketBeat

Mar 09, 2026

Jefferies Financial Group Acquires Stake in PTC Therapeutics - National Today

Mar 09, 2026

Jefferies Financial Group Inc. Acquires Shares of 1,584,678 PTC Therapeutics, Inc. $PTCT - MarketBeat

Mar 09, 2026

Mar 08, 2026

Ideas Watch: Will PTC Therapeutics Inc. benefit from government policy2026 Setups & Safe Entry Trade Signal Reports - baoquankhu1.vn

Mar 08, 2026

Mar 06, 2026

Dividend Watch: Is PTC Therapeutics Inc a stock for growth or value investorsMarket Volume Summary & Weekly Stock Performance Updates - baoquankhu1.vn

Mar 06, 2026

Royce & Associates LP Has $2.01 Million Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat

Mar 06, 2026

Mar 05, 2026

Neil G. Almstead sells multiple PTCT lots (PTCT) — Form 144 details - Stock Titan

Mar 05, 2026

Mar 03, 2026